FRMD3 gene: Its role in diabetic kidney disease. A narrative review

Diabetology and Metabolic Syndrome

Volumn 7, Issue 1, 2015, Pages

  Buffon, Marjoriê Piuco ^a,b   Sortica, Denise Alves ^a,b   Gerchman, Fernando ^a,b   Crispim, Daisy ^a,b   Canani, Luís Henrique ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE; DIABETIC NEPHROPATHY; ETHNICITY; FRMD3 GENE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE SILENCING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84952312347     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/s13098-015-0114-4     Document Type: Review

References (58)

1. Association AD. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37(Suppl 1):S14-80.
2. Association AD. Standards of medical care in diabetes: summary of revisions. Diabetes Care. 2015;38(Suppl):S4.
3. Sortica DA, et al. The role of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 in diabetic nephropathy. Arq Bras Endocrinol Metabol. 2011;55(9):677-85.
4. Levey AS, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089-100.
5. Bloomgarden ZT. Diabetic nephropathy. Diabetes Care. 2008;31(4):823-7.
6. Bruno RM, Gross JL. Prognostic factors in Brazilian diabetic patients starting dialysis: a 3.6-year follow-up study. J Diabetes Compl. 2000;14(5):266-71.
7. de Boer IH et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 305(24):2532-9
8. Dwyer JP et al. Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: results from the DEMAND Study. Cardiorenal Med. 2(1): 1-10.
9. Kramer H. Screening for kidney disease in adults with diabetes and prediabetes. Curr Opin Nephrol Hypertens. 2005;14(3):249-52.
10. Kramer CK, et al. Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care. 2007;30(8):1998-2000.
11. Ada ADA. Standards of medical care in diabetes-2006. Diabetes Care. 2006;29(Suppl 1):S4-42.
12. ADA. Standards of medical care in diabetes-2013. Diabetes Care. 36(Suppl 1): S11-66.
13. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825-30.
14. KDIGO. clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2012; Suppl: S1-S150.
15. Chaturvedi N, et al. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int. 2001;60(1):219-27.
16. Adler AI, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225-32.
17. Krolewski AS. Genetics of diabetic nephropathy: evidence for major and minor gene effects. Kidney Int. 1999;55(4):1582-96.
18. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes. 2000;49(9):1399-408.
19. Perkins BA, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348(23):2285-93.
20. Canani LH, Gerchman F, Gross JL. Familial clustering of diabetic nephropathy in Brazilian type 2 diabetic patients. Diabetes. 1999;48(4):909-13.
21. Yajima Y, Nakajima S. Familial clustering and genetics of diabetic nephropathy. Nihon Rinsho. 1997;55(Suppl):795-801.
22. Martini S, et al. Defining human diabetic nephropathy on the molecular level: integration of transcriptomic profiles with biological knowledge. Rev Endocr Metab Disord. 2008;9(4):267-74.
23. Pezzolesi MG, Krolewski AS. Diabetic nephropathy: is ESRD its only heritable phenotype? J Am Soc Nephrol. 2013;24(10):1505-7.
24. Pezzolesi MG, Krolewski AS. The genetic risk of kidney disease in type 2 diabetes. Med Clin North Am. 2013;97(1):91-107.
25. Pezzolesi MG, et al. Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes. 2009;58(6):1403-10.
26. Maeda S, et al. Replication study for the association between four Loci identified by a genome-wide association study on European American subjects with type 1 diabetes and susceptibility to diabetic nephropathy in Japanese subjects with type 2 diabetes. Diabetes. 2010;59(8):2075-9.
27. Ng DP, Krolewski AS. Molecular genetic approaches for studying the etiology of diabetic nephropathy. Curr Mol Med. 2005;5(5):509-25.
28. Freedman BI, et al. Genetic factors in diabetic nephropathy. Clin J Am Soc Nephrol. 2007;2(6):1306-16.
29. Mooyaart AL, et al. Genetic associations in diabetic nephropathy: a meta-analysis. Diabetologia. 2011;54(3):544-53.
30. Williams WW, et al. Association testing of previously reported variants in a large case-control meta-analysis of diabetic nephropathy. Diabetes. 2012;61(8):2187-94.
31. Lohmueller KE, et al. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet. 2003;33(2):177-82.
32. Carpena MP, et al. Genetics of diabetic nephropathy. Arq Bras Endocrinol Metabol. 2010;54(3):253-61.
33. Zeggini E, Ioannidis JP. Meta-analysis in genome-wide association studies. Pharmacogenomics. 2009;10(2):191-201.
34. McKnight AJ, McKay V, Maxwell AP. Genetic and epigenetic risk factors for diabetic kidney disease. Adv Chronic Kidney Dis. 21(3): 287-96.
35. Ni X, et al. Molecular cloning and characterization of the protein 4.1O gene, a novel member of the protein 4.1 family with focal expression in ovary. J Hum Genet. 2003;48(2):101-6.
36. Hoover KB, Bryant PJ. The genetics of the protein 4.1 family: organizers of the membrane and cytoskeleton. Curr Opin Cell Biol. 2000;12(2):229-34.
37. Ramez M, et al. Distinct distribution of specific members of protein 4.1 gene family in the mouse nephron. Kidney Int. 2003;63(4):1321-37.
38. Chishti AH, et al. The FERM domain: a unique module involved in the linkage of cytoplasmic proteins to the membrane. Trends Biochem Sci. 1998;23(8):281-2.
39. Baines AJ. A FERM-adjacent (FA) region defines a subset of the 4.1 superfamily and is a potential regulator of FERM domain function. BMC Genom. 2006;7:85.
40. Takakuwa Y. Protein 4.1, a multifunctional protein of the erythrocyte membrane skeleton: structure and functions in erythrocytes and nonerythroid cells. Int J Hematol. 2000;72(3):298-309.
41. Pasternack GR, et al. Interactions between protein 4.1 and band 3. An alternative binding site for an element of the membrane skeleton. J Biol Chem. 1985;260(6):3676-83.
42. Lombardo CR, Willardson BM, Low PS. Localization of the protein 4.1-binding site on the cytoplasmic domain of erythrocyte membrane band 3. J Biol Chem. 1992;267(14):9540-6.
43. Marfatia SM, et al. Identification of the protein 4.1 binding interface on glycophorin C and p55, a homologue of the Drosophila discs-large tumor suppressor protein. J Biol Chem. 1995;270(2):715-9.
44. Nunomura W, et al. Regulation of CD44-protein 4.1 interaction by Ca2+ and calmodulin. Implications for modulation of CD44-ankyrin interaction. J Biol Chem. 1997;272(48):30322-8.
45. Schischmanoff PO, et al. Defining of the minimal domain of protein 4.1 involved in spectrin-actin binding. J Biol Chem. 1995;270(36):21243-50.
46. Walensky LD, et al. The 13-kD FK506 binding protein, FKBP13, interacts with a novel homologue of the erythrocyte membrane cytoskeletal protein 4.1. J Cell Biol. 1998;141(1):143-53.
47. Mattagajasingh SN, et al. A nonerythroid isoform of protein 4.1R interacts with the nuclear mitotic apparatus (NuMA) protein. J Cell Biol. 1999;145(1):29-43.
48. Kramer-Zucker AG, et al. Organization of the pronephric filtration apparatus in zebrafish requires Nephrin, Podocin and the FERM domain protein Mosaic eyes. Dev Biol. 2005;285(2):316-29.
49. Wei X, et al. Kindlin-2 regulates renal tubular cell plasticity by activation of Ras and its downstream signaling. Am J Physiol Renal Physiol. 2013;306(2):F271-8.
50. Martini S, et al. From single nucleotide polymorphism to transcriptional mechanism: a model for FRMD3 in diabetic nephropathy. Diabetes. 2013;62(7):2605-12.
51. Pezzolesi MG, et al. Family-based association analysis confirms the role of the chromosome 9q21.32 locus in the susceptibility of diabetic nephropathy. PLoS One. 2013;8(3):e60301.
52. Dolan V, Hensey C, Brady HR. Diabetic nephropathy: renal development gone awry? Pediatr Nephrol. 2003;18(2):75-84.
53. Hu C, et al. CPVL/CHN2 genetic variant is associated with diabetic retinopathy in Chinese type 2 diabetic patients. Diabetes. 2011;60(11):3085-9.
54. Palmer ND, Freedman BI. Diabetic nephropathy: FRMD3 in diabetic nephropathy-guilt by association. Nat Rev Nephrol. 2013;9(6):313-4.
55. Freedman BI, et al. Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans. PLoS Genet. 2011;7(6):e1002150.
56. Park H, et al. A family-based association study after genome-wide linkage analysis identified two genetic loci for renal function in a Mongolian population. Kidney Int. 2013;83(2):285-92.
57. Palmer ND, et al. Evaluation of candidate nephropathy susceptibility genes in a genome-wide association study of African American diabetic kidney disease. PLoS One. 2014;9(2):e88273.
58. Pezzolesi, M.G., et al., An intergenic region on chromosome 13q33.3 is associated with the susceptibility to kidney disease in type 1 and 2 diabetes. Kidney Int. 80(1): 105-11.